Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECTINIUM-2: [225Ac]Ac-AKY-1189 in Advanced Solid Tumors
NCT07020117Phase 1Recruiting
- Sponsor
- Aktis Oncology
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Cyclic Peptides, Stapled Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AKY-1189 in solid tumor, sponsored by Aktis Oncology. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events by Severity and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
AKY-1189
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07020117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020117.